Anabolic-Androgenic Steroids

Norethandrolone is an anabolic steroid which is closely related to the steroid nandrolone in its structure. Although this steroid is essentially nandrolone modified to make oral dosing viable, it cannot be looked at as simply an oral alternative to Deca Durabolin. Norethandrolone was first developed in the 1950s. It was then developed into a prescription medication by the the pharmaceutical company Searle, which introduced it to the US prescription drug market under the brand name of Nilevar in the late 1950s.The drug was originally sold as an oral tablet, and oral solution, and an injectable solution in ampoules. The inectable form of this drug has been out of commerce for so long that few even remember that it ever existed. Nilevar was prescribed for a variety of illnesses that could be benefited by a protein sparing anabolic agent. Listed indications included preparation for and recovery from surgery, severe or prolonged illness, anorexia nervosa, severe burns and trauma, decubitus, ulcers, bone fracture healing and various forms of malnourishment in adults and children. Norethandrolone ultimately saw only limited success as a prescription anabolic agent. It did make its way to Europe and certain other markets, but not widely. Today, this drug is available on a limited basis, mainly in Australia where it remains a popular substance on the veterinary drug market.

Miotolan is an oral anabolic derived from dihydrotestosterone. This agent is moderately anabolic, with only mild androgenic properties. This is no doubt due to the modification of the steroid’s A-ring, which allows the steroid structure to stay stable and bind receptors in muscle tissue long enough to provide an anabolic benefit. Furazabol was first developed in the 1960s. The only modern pharmaceutical preparation o f record containing furazabol, at least known to researches in the West, was miotolan from Daiichi Seiyaku Labs in Japan, which was sold in Japan mainly during the 1970’s and 80’s. The drug itself is scarcely mentioned in the Western medical literature, and consequently a great deal of myth has come to surround it around athletes. A realistic appraisal sits this drug in a very similar class to winstrol, however, with both agents being moderately strong anabolics with low androgenic activity. Aside from this, it is difficult to ascribe any drastically unique traits to this drug. Today, furazabol is very scarcely known to bodybuilders and athletes. The Miotolan brand from Japan was discontinued many years ago, and no pharmaceutical preparation containing furazabol has been known to exist since. The drug is still located on the black market, however, due to the fact that raw powder is still being produced in Asia. Currently, the actual number of products containing this drug is small, although it could easily expand if the market ever created a demand. It is unlikely that an actual prescription agent containing this substance will ever be seen again.

Methyl 1 testosterone is an oral anabolic steroid which is derived from the hormone dihydrotestosterone. It is closest in structure to the hormone dihydroboldenone differing only by the addition of c-17 alkylation which changes the activity of this drug considerably. Methyl 1 testosterone was first developed in the 1960s. This compound was developed during some of the most active years of steroid research, a time when literally hundreds of different effective anabolic agents were being actively studied and persued by pharmaceutical companies. Although this substance showed some very favorable qualities and a desirable anabolic to androgenic ratio, like many other compounds developed during this time, Methyl 1 testosterone was never actually produced and marketed for any medical purposes. After this, the drug was pretty much forgotten about and laid dormant in the pages of medical books and research journals for around 40 years. The drug then reemerged sharply in 2003, when it was marketed as an over the counter supplement in the United States, which was possible due to the fact that it was virtually unknown during the time the 1991 anabolic steroids laws were written, and therefore wasn’t included. However, production was discontinued after the laws were reformed in 2005 to include this substance as a controlled anabolic steroid. Currently there is no prescription drug containing this compound.

MENT, which is short for methylnortestosterone, is an anabolic steroid which is a derivative of the hormone nandrolone. This product is less commonly referred to trestolone acetate. MENT was first developed in the 1960’s, but never gained much popularity in the drug community and therefore was never made it to becoming a commercially sold drug product. Recently however, the large pharmaceutical company Schering AG made a public statement that it had reached an agreement with an outside company to research, market and develop MENT as a prescription drug. Schering has said publicly that MENT will be an easier to administer yet equally effective steroid as is testosterone products for the purposes for which it is prescribed. It is suspected that the drug will be made available in an implant preparation, in which implants will be placed inside the user and will then yield a gradual release of the hormone into the body’s system. If the drug is marketed into an implant, it will most likely be impractical to use for bodybuilding and performance enhancing purposes unless it can somehow be converted into an injectable preparation.

Drostanolone propionate is an injectable anabolic steroid derived from dihydrostestosterone (DHT). Here, the DHT has been modified with a 2-methyl group to increase its anabolic properties, making this drug much more effective at promoting muscle growth than the non-methylated DHT. Drostanolone propionate was founded in the 1950’s. A company called Syntex developed the compound along with such other well known steroids as Anadrol and Superdrol. Around ten years later masteron drostanolone was first introduced as a prescription medication. In the US, the FDA approved drostanolone for use in postmenopausal women for the treatment of inoperable breast cancer. Eventually other prescription medications were developed which better served the same conditions that this drug was originally approved for, and slowly manufacturers began to voluntarily discontinue production of it. Now days, this drug is no longer available as a prescription drug and can only be purchased on the black market where it is still a popular compound amongst the bodybuilding and performance enhancing community.